The results suggest that expanded but ineffective erythropoietic activity in these patients leads to inappropriately low hepcidin levels in MDS-RARS patients with an SF3B1 mutation, leading ultimately to excess release of iron from the RES and parenchymal iron loading (Ambaglio et al., 2013). Here, SF3B1 is linked to myelodysplastic syndrome.